mbiomics GmbH
Germany
- Munich, Bavaria
- 24/03/2023
- Series A
- $13,945,000
We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life.
- Industry Biotechnology Research
- Website https://mbiomics.com/
- LinkedIn https://www.linkedin.com/company/mbiomics-gmbh/
Related People
Laura FigullaCo Founder
Germany -
Munich, Bavaria
With 15+years of life science entrepreneurial and strategy&transactions consulting experience, including venture capital, M&A, digital transformation and innovation strategy, as well as in-depth industry expertise and strong public relations skills, I am truly passionate about creating company strategies, vision and enabling high-performing teams. My career background allows me to provide strategic, fundraising, and business operations insight for innovative life sciences players, in particular around digital health and biotechnology business models.
Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)